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Abstract We have previously highlighted the ability
of testosterone (T) to improve differentiation and
myotube hypertrophy in fusion impaired myoblasts
that display reduced myotube hypertrophy via multi-
ple population doublings (PD) versus their parental
controls (CON); an observation which is abrogated via
PI3K/Akt inhibition (Deane et al. 2013). However,
whether the most predominant molecular mechanism
responsible for T induced hypertrophy occurs directly
via androgen receptor or indirectly via IGF-IR/PI3K/
Akt pathway is currently debated. PD and CON C2C12
muscle cells were exposed to low serum conditions in
the presence or absence of T (100 nM) ± inhibitors of
AR (flutamide/F, 40 lm) and IGF-IR (picrop-
odophyllin/PPP, 150 nM) for 72 h and 7 days (early/
late muscle differentiation respectively). T increased
AR and Akt abundance, myogenin gene expression,
and myotube hypertrophy, but not ERK1/2 activity in
both CON and PD cell types. Akt activity was not
increased significantly in either cell type with T.
Testosterone was also unable to promote early differ-
entiation in the presence of IGF-IR inhibitor (PPP) yet
still able to promote appropriate later increases in
myotube hypertrophy and AR abundance despite IGF-
IR inhibition. The addition of the AR inhibitor
powerfully attenuated all T induced increases in
differentiation and myotube hypertrophy with corre-
sponding reductions in AR abundance, phosphory-
lated Akt, ERK1/2 and gene expression of IGF-IR,
myoD and myogenin with increases in myostatin
mRNA in both cell types. Interestingly, despite
basally reduced differentiation and myotube hyper-
trophy, PD cells showed larger T induced increases in
AR abundance vs. CON cells, a response abrogated in
the presence of AR but not IGF-IR inhibitors.
Furthermore, T induced increases in Akt abundance
were sustained despite the presence of IGF-IR inhibi-
tion in PD cells only. Importantly, flutamide alone
reduced IGF-IR mRNA in both cell types across time
points, with an observed reduction in activity of ERK
and Akt, suggesting that IGF-IR was transcriptionally
regulated by AR. However, where testosterone
increased AR protein content there was no increases
D. C. Hughes  C. E. Stewart  H. F. Dugdale 
F. Yousefian  A. P. Sharples (&)
Stem Cells, Ageing & Molecular Physiology Unit,
Research Institute for Sport and Exercise Sciences
(RISES), School of Sport and Exercise Sciences,
Liverpool John Moores University, Liverpool, UK
e-mail: a.sharples@ljmu.ac.uk;
a.p.sharples@googlemail.com
D. C. Hughes
Department of Neurobiology, Physiology and Behavior,
University of California, Davis, CA, USA
N. Sculthorpe
Institute for Clinical Exercise and Health Science
(ICEHS), University of the West of Scotland, Hamilton,
Scotland, UK
M. P. Lewis
National Centre for Sport and Exercise Medicine, School
of Sport, Exercise and Health Science, Loughborough
University, Loughborough, UK
123
Biogerontology
DOI 10.1007/s10522-015-9621-9
observed in IGF-IR gene expression. This suggested
that sufficient AR was important to enable normal
IGF-IR expression and downstream signalling, yet
elevated levels of AR due to testosterone had no
further effect on IGF-IR mRNA, despite testosterone
increasing Akt abundance in the presence of IGF-IR
inhibitor. In conclusion, testosterones ability to
improve differentiation and myotube hypertrophy
occurred predominately via increases in AR and Akt
abundance in both CON and PD cells, with fusion
impaired cells (PD) showing an increased responsive-
ness to T induced AR levels. Finally, T induced
increases in myotube hypertrophy (but not early
differentiation) occurred independently of upstream
IGF-IR input, however it was apparent that normal
AR function in basal conditions was required for
adequate IGF-IR gene expression and downstream
ERK/Akt activity.
Keywords Testosterone  Akt  Satellite cell 
Muscle  IGF-I  Aging  Androgens
Introduction
The regulation of skeletal muscle mass is reliant on the
balance between hypertrophy (e.g. protein synthesis/
anabolism) and atrophy (e.g. protein break-
down/catabolism). A potential clinical intervention for
promoting a positive net balance in the favor of protein
synthesis is Testosterone (T) administration (Brodsky
et al. 1996; Sheffield-Moore et al. 1999). Indeed, it has
been suggested that testosterone replacement therapy
can increasemuscle strength andmass in various clinical
populations, including patients with age related decline
in muscle size and strength (sarcopenia) (Bhasin et al.
2000; Ferrando et al. 2002; Casaburi et al. 2004; Sattler
et al. 2011; Dillon et al. 2012). In rodents, Serra et al.
(2013b) observed T induced increases in skeletal muscle
regeneration in both young and aged mice post
cardiotoxin injury, which culminated in increased satel-
lite cell activation and number. Further, testosterone-
filled implants administered to young and old mice
resulted in increases in gastrocnemius muscle weight
and fiber cross-sectional area. The preservation of
muscle mass was accompanied by decreases in myo-
statin and restoration of aged induced reductions in Akt
activity and notch signaling (Kovacheva et al. 2010).
Most recently, using murine heterochronic parabiotic
models, testosterone administration in castrated oldmice
restored gastrocnemius muscle weight, muscle fiber
cross-sectional area, and notch-1 expression (Sinha et al.
2014); observations that were not apparent when
testosterone was absent. Interestingly, in humans
Sinha-Hikim et al. (2006) observed increased myogenin
expression with graded doses of T administered in
community-dwelling older men, which was also accom-
panied by increasedmuscle size compared to baseline. A
finding that was substantiated with T administration in
frail elderly men where a prevention of aged related
muscle loss occurred during a 6 month period compared
to the placebo group (Atkinson et al. 2010). Finally, in
terms of muscle atrophy, testosterone has been demon-
strated to preventmusclemass reductions in 2-month old
castrated mice (Serra et al. 2013a), and restore normal
transcript levels of myostatin and atrogenes (Atrogin-1
and MuRF1) following androgen deprivation (De
Naeyer et al. 2014). Collectively these studies highlight
the potential of T administration in restoring aged and
atrophying muscle phenotypes to those of young adults.
However, it is only recently that studies have begun to
investigate the molecular role of testosterone in skeletal
muscle cell growth, differentiation, and hypertrophy
during periods of muscle loss with age (Wu et al. 2010;
White et al. 2012; Serra et al. 2013b).
In vitro muscle cell studies have been conducted to
provide potential mechanisms of Ts action indepen-
dently of age (Wannenes et al. 2008; Wu et al. 2010;
Serra et al. 2011; Sculthorpe et al. 2012; Basualto-
Alarco´n et al. 2013). The majority of these studies
demonstrate increases in differentiation and myotube
hypertrophy with T in muscle cell culture. T has also
been co-incubated with inhibitors for the AR, IGF-IR,
Akt and mTOR in a number of cell lines and primary
cultures (Wannenes et al. 2008; Wu et al. 2010; Serra
et al. 2011; Sculthorpe et al. 2012; Basualto-Alarco´n
et al. 2013; Deane et al. 2013) in order to elucidate the
mechanisms of T induced muscle hypertrophy. How-
ever, these pathwayswere studied in isolation and there
is currently no information about the most predomi-
nant mechanism of T induced growth either via a
potential ‘indirect’ increase in IGF-I gene expression
and associated signaling, which has more recently
been suggested to be important in regulating T induced
hypertrophy (Serra et al. 2011; Sculthorpe et al. 2012;
White et al. 2012), versus the traditionally ‘direct’
androgen receptor mediation (Lee 2002; Altuwaijri
et al. 2004; Wannenes et al. 2008). Furthermore, we
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have recently shown that PI3K inhibitor (LY294002)
attenuates the testosterone induced increases in differ-
entiation and myotube hypertrophy, suggesting that
IGF-I/IGF-IR and downstream signaling are important
in mediating testosterones action (Deane et al. 2013).
In order to elucidate the combined pathways that
control both muscle cell adaptation and ageing, our
recent studies have highlighted two myoblast models
to study reduced differentiation capacity and myotube
atrophy (Sharples et al. 2010, 2011). The first model
investigated parental mouse C2 myoblasts versus their
daughter C2C12 cells (subclone). Despite shared ori-
gins, the parental C2 cells displayed slower and
diminished differentiation profiles compared to the
daughter C2C12 cells and were also more susceptible
to TNF-a-induced inhibition of differentiation and
induction of cell death (Sharples et al. 2010, 2015). The
second model utilized C2C12 cells that had undergone
58 population doublings (PD) versus parental control
cells (CON), which have undergone no doublings
relative to the PD cells (Sharples et al. 2011). Like C2
cells in the firstmodel and relative to theCONcells, the
PD cells also displayed impaired differentiation in
monolayer (Sharples et al. 2011) and reduced myotube
hypertrophy in both monolayer (Deane et al. 2013) and
bioengineered three-dimensional (3D) culture systems
(Sharples et al. 2012). PD cells also had a reduced
number of cells exiting the cell cycle in G1 (pre-
requisite for fusion), with corresponding decreases in
gene transcripts controlling fusion such (myoD, myo-
genin, IGF-I) and reduced activation of Akt with
parallel increases in fusion inhibitory factors such as;
IGFBP5 mRNA and JNK activation (Sharples et al.
2011) versus control cells. Further basally, PD cells
had higher myostatin (negative regulator of muscle
mass) and lower mTOR gene expression (required for
differentiation/myotube hypertrophy) in mature myo-
tubes (Deane et al. 2013). These adaptations were
confirmed in 3D bioengineered muscle systems
(Sharples et al. 2012) where myostatin mRNA
increased as did TNF-a transcript expression with
reductions in peak force generation by the cells on
attachment to the 3D matrix (Sharples et al. 2012).
Importantly, PD cells therefore displayed a similar
gene transcript (decreased myoD, myogenin, IGF-I
and increased TNF-a and myostatin), signaling pro-
cesses (e.g. reduced phosphorylated Akt) and mor-
phology (impaired differentiation and myotube
atrophy) to that previously observed following
replicative aging in isolated humanmuscle cells (Bigot
et al. 2008), in human/rodent cells isolated from aged
individuals (Lees et al. 2006; Bigot et al. 2008; Leger
et al. 2008; Lees et al. 2009; Pietrangelo et al. 2009)
and from that observed in aged bioptic material (Welle
et al. 2003; Leger et al. 2008). Critically, in this model
the reduction in fusion in PD cells was not associated
with senescence as there was no reduction in S/G2
phase cell cycle progression and the doubling times of
the cells following multiple population doublings was
not altered (Sharples et al. 2011). Thus, this multiple
population doubled cellular model can be used as a
representative model to investigate mechanisms of
impaired differentiation and myotube atrophy, pheno-
types similar to those observed in aged muscle cells.
Previous work with this model has also demonstrated
that T administration (100 nM) has been observed to
improve impaired differentiation and myotube hyper-
trophy in PD cells to levels observed in control cells
under basal conditions (Deane et al. 2013).
Consequently, as the primary signalingmechanisms
for testosterone induced hypertrophy requires further
investigation, and the mechanisms of T induced
hypertrophy with age have yet to be fully determined,
the aim of the current studies were to investigate: (1)
The predominant pathway (androgen receptor vs. the
IGF-I receptor and associated signaling ERK, Akt) that
mediated the hypertrophic effects of testosterone using
specific substrate competitors for AR and IGF-IR
(flutamide and picropodophyllin, respectively) inde-
pendently, and combination in the absence or presence
of testosterone, and to investigate, (2) the role of these
pathways in T induced differentiation and myotube
hypertrophy in muscle cells that are fusion impaired
and display characteristics of myotube atrophy (PD
cells) versus relevant controls. It was hypothesized that
the inhibition of the AR and IGF-I receptor would both
impair testosterone induced increases in myotube
differentiation and hypertrophy with PD cells rendered
more susceptible versus CON cells.
Methods
Cell culture
Murine C2C12 (Yaffe and Saxel 1977; Blau et al. 1985)
(ATCC, Rockville, MD, USA) skeletal muscle
myoblasts were seeded at 80,000 cells/ml in 2 ml
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growth media (GM) per well. GM was made up of:
Dulbecco’s modifed eagle’s medium, DMEM (Sigma,
Dorset, UK. Cat no. D6429), 20 % fetal bovine serum
(FBS) (PAA, Somerset, UK) and 1 % PenStrep
(Invitrogen, Paisley, UK) Wells were coated with
0.2 % porcine gelatin (Sigma, Dorset, UK) using
6-well plates (Fisher Scientific, Loughborough, UK)
and grown in a humidified 5 % CO2 atmosphere at
37 C. Population doubled (PD) cells and their
parental controls (CON) were developed as detailed
by Sharples et al. (2011, 2012). Briefly, PD cells were
subjected to 58–60 population doublings vs. the
parental CON cells, that have undergone no doublings
relative to the PD cells (Sharples et al. 2011). Further,
the PD cells have reduced differentiation and display
myotube atrophy at 72 h (Sharples et al. 2011) and 7
days (Deane et al. 2013) versus the parental CON
cells. Once confluent, the myoblasts were transferred
to low serum media/differentiation media (DM; com-
posed of: DMEM, 2 % horse serum (HS), 1 %
Penstrep), which promotes the spontaneous fusion of
the myoblasts into multinucleated myotubes (Blau
et al. 1985). Cells were incubated in DM for 30 min at
37 C in a 5 % CO2 atmosphere with this period of
equilibration denoted as the 0 h time point. Cells at the
time points of 72 h and 7 days (early and late muscle
differentiation respectively) were fixed for subsequent
morphology analyses, mRNA extracted for gene
expression studies via reverse transcription quantita-
tive real-time polymerase chain reaction (rt-qRT-
PCR) and lysed for cell signaling analyses via SDS
PAGE and Western blot (all detailed below).
Cell treatments
All treatments were administered in DM described
above. Initial dose responses were initially performed
for AR inhibitor (flutamide/F 20 and 40 lm) and IGF-
IR inhibitor; picropodophyllin/PPP 30, 90 and
150 nM) to ascertain the most effective treatment
(e.g. via optimum reductions in total AR content for
flutamide and via reduction in Akt and ERK activation
for IGF-IR inhibition). At 40 lM Flutamide reduced
AR by over 70 % in CON and in PD cells after 72 h
and 150 nM Picropodophyllin reduced Akt by an
average of*43 % and ERK1/2 by 32 % across both
CON and PD cells over both 30 min and 72 h post DM
transfer. Following optimisation; the treatments com-
prised of a vehicle control (differentiation media/DM
alone plus DMSO at a concentration of 0.01 %),
testosterone (100 nM as used in Deane et al. 2013),
flutamide (40 lM), picropodophyllin (150 nM), co-
incubations of the inhibitors with T (i.e. T ? F,
T ? PPP, T ? F ? PPP). For both results and fig-
ure legends the following nomenclature for dosing
conditions will be used: Control (DM conditions
above), testosterone (T), flutamide (F), and picrop-
odophyllin (PPP) respectively. All treatments were
added at 0 h and existing media was further supple-
mented with 1 ml of fresh media at 72 h for cells that
were maintained to 7 days.
RNA isolation
Six-well plates for each time point (0, 72 h and 7 days)
were washed with 1 ml/well phosphate buffer saline
(PBS) and extracted for RNA using 300 ll TRIzolTM
Reagent/well (Sigma, Poole, UK). Total RNA was
extracted by following manufacturer’s instructions.
RNA concentration and purity were assessed through
UV spectroscopy at ODs of 260 and 280 nm, using the
Nanodrop spectrophotometer 2000c (Fisher, Rosklide,
Denmark). Samples had 260:280 ratios between 1.8
and 2.2.
Primer design
Primer sequences (Table 1)were identified usingGene
(NCBI, www.ncbi.nlm.nih.gov/gene) and designed
using both web-based OligoPerfectTM Designer (In-
vitrogen, Carlsbad, CA, USA) and Primer-BLAST
(NCBI, http://www.ncbi.nlm.nih.gov/tools/primer-
blast). Sequence homology searches ensured speci-
ficity with no un-intended targets identified. Three or
more GC bases in the last five bases at the 30 end of the
primer were avoided. Secondary structure interactions
(hairpins, self-dimer and cross dimer) within the pri-
mer were also avoided. All primers ranged between 18
and 23 bp and amplified a product between 125 and
197 bp. GC content was between 36.3 and 60.0 %
(Table 1). Primers without the requirement of further
purification were purchased from Sigma (Poole, UK).
Reverse transcription quantitative real time
polymerase chain reaction (rt-qRT-PCR)
Seventy ng RNA/sample was reverse transcribed and
amplified using QuantiFastTM SYBRGreen RT-PCR
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one-step kit on a Rotogene 3000Q (Qiagen, Crawley,
UK) supported by Rotogene software (Hercules, CA,
USA). The rt-qRT-PCR was performed as follows:
10 min, 50 C (reverse transcription), 5 min 95 C
(transcriptase inactivation and initial denaturation),
followed by: 10 s, 95 C (denaturation), 30 s, 60 C
(annealing and extension) for 40 cycles. Following
completion, melting curve analyses were performed to
exclude primer-dimer, contamination and non-specific
amplification. All melt curves confirmed that single
peak melt temperatures occurred for each gene of
interest. Relative mRNA expression was quantified for
myogenin, MyoD, AR, IGF-IR and myostatin
(Table 1) using the comparative Ct (DDct) method
(Livak and Schmittgen 2001; Schmittgen and Livak
2008; Sharples et al. 2011) against a stable reference
gene of polymerase (RNA) II polypeptide B (RP-IIb)
(combined stable Ct value for all runs across exper-
imental conditions 17.36 ± 1.03) and calibrator of
CON cells at 0 h.
SDS PAGE and immunoblotting
At the relevant time points cells were washed twice in
1 ml/well PBS and lysed in 300 ll/well (six well
plates) using 10 mM TrisHCl, 5 mM EDTA, 50 mM
sodium chloride, 30 mM sodium pyrophosphate,
50 mM sodium fluoride, 100 lM sodium orthovana-
date, 1 mM PMSF, 1 % Triton X-100 and protease
inhibitor tablets (Roche Diagnostics Limited, UK).
Thirty lg of protein per cell lysate was added to
sample buffer (59 Laemmili Buffer; 1 M Tris–HCl
pH 6.8, SDS, Glycerol, dH2O, gel loading solution
(Sigma Aldrich, Poole, UK) and b-mercaptoethanol).
Molecular weights were determined by the incorpo-
ration of 10 ll rainbow molecular weight protein
standards purchased from Sigma-Aldrich (Color Burst
Electrophoresis Marker, Sigma, Poole, UK). The
samples were boiled at 90 C for 5 min before loading
onto the gel with a 20 ll loading tip (Fisher Scientific,
Loughborough, UK).
Gels were made up of a 10 % resolving gel (30 %
acrylamide 1 % BIS, 1.5 M Tris base pH 8.9, 0.1 M
EDTA pH 7.4, 10 % SDS, 0.1 % (w/v) APS and 0.1 %
(v/v) TEMED) and a 5 % stacking gel (30 %
acrylamide 1 % BIS, 54 mM Tris HCl pH 6.8,
0.1 M EDTA pH 7.4, 0.1 % (w/v) SDS, 0.1 % (w/v)
APS and 0.1 % (v/v) TEMED). Samples were elec-
trophoresed at 200 volts until proteins migrated to the
bottom of the gels. The proteins were transferred using
a semi dry technique (Trans blot turbo transfer system;
Bio-Rad Laboratories, Inc. Hercules, CA, USA) to the
nitrocellulose membrane for use in immunoblotting
for 30 min. Immunoblotting was performed using a
fast western supersignal west pico rabbit substrate kit
(Pierce, Rockford, IL, USA). The western blotting was
performed based on manufacturers instructions. Mem-
branes were incubated in primary antibodies (New
England Bio Labs, Santa Cruz, USA) for the following
proteins: p-Akt (ser473) cat no. 4058, p-ERK1/2
(Thr202/Tyr204) cat no. 9101, total Akt cat no. 9272,
total ERK1/2 cat no. 9102 all at a concentration of
1:1000, total AR (1:500) cat no. SC-816, and GAPDH
(loading control; 1:4000) cat no. 5174, were diluted in
Table 1 Primer sequences for genes of interest
Gene Primer sequence (50–30) Ref. sequence number Amplicon length (bp) GC% content
AR F:GCCTCCGAAGTGTGGTATCC
R:CCTGGTACTGTCCAAACGCA
NM_013476.3 138 60
55
IGF-IR F:CTACCTCCCTCTCTGGGAATG
R:GCCCAACCTGCTGTTATTTCT
NM_010513 185 47.4
47.4
MyoD F:CATTCCAACCCACAGAAC
R:GGCGATAGAAGCTCCAA
NM_010866 125 59.7
50
Myostatin F:TACTCCGAATAGAAGCCATAA
R:GTAGCGTGATAACGTCATC
NM_010834 194 36.3
45
Myogenin F:CCAACTGAGATTGTCTGTC
R:GGTGTTAGCCTTATGTGAAT
NM_031189 173 47.3
40
RP-IIb F:GGTCAGAAGGGAACTTGTGGTAT
R:GCATCATTAAATGGAGTAGCGTC
NM_153798.1 197 50
44.4
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an antibody diluent liquid (contained in the fast
western supersignal pico rabbit substrate kit described
above) and incubated overnight at 4 C. Detection of
proteins was achieved using enhanced chemilumines-
cence (ECL) with a West Pico Supersignal kit (Pierce,
Rockford, IL, USA). The total and phosphorylated
proteins were assessed relative to the GAPDH that was
unchanged between conditions. Total AR, p-Akt and
GAPDH were analysed on the same membrane due to
distinct molecular weights. Phosphorylated ERK and
GAPDH were also analyzed on the same membranes.
Membranes were then stripped and re-probed for total
ERK and Akt. Although proteins (p-Akt and p-ERK1/
2) were analyzed on separate membranes between cell
types i.e. (CON vs. PD, when mean ± SD were
calculated globally for the arbitrary units (following
detection), these were found to be non-significant
between cell types (e.g. p-ERK1/2 72 h: CON
0.11 ± 0.02 vs. PD 0.16 ± 0.03; P = NS). Therefore
comparisons between cell types were enabled. For the
total AR protein, the same exposure times and batch of
antibodies were selected for densitometry analysis
allowing for comparison between CON and PD cell
types.
Morphology
Cells were fixed by media being aspirated from the
wells and replaced with 1 ml PBS and 0.5 ml of
methanol/0.5 ml acetone ice-cold per well for 10 min
and then 1 ml of acetone/1 ml of acetone per well for a
further 10 min. PBS (2 ml/well) was added after
removal of the methanol/acetone mix and plates were
stored in 4 C until further analysis. Cells were stained
for desmin and nuclei using 1:200 desmin polyclonal
rabbit anti-human (also reacts with mouse) antibody
(Abcam, Cambridge, UK), 1:200 anti-rabbit TRITC
secondary antibody (Sigma, St Louis, USA) and
1:2000 Sytox Green (Life Technologies, CA, USA)
nuclear stain. The blocking/permeabilisation solution
consisted of 19 TBS (pH 8.5), 5 % goat serum (Sigma
Aldrich, Poole, UK) and 0.2 % Triton-X 100 (Fisher
Scientific, Loughborough, UK). The antibody solu-
tions consisted of 19 TBS, 2 % goat serum and 0.2 %
Triton-X 100 plus either the primary or secondary
antibody at concentrations described above. Sytox
green was diluted in double distilled water. Myotubes
were defined as 3? nuclei within a cellular structure so
to rule out cells undergoing mitosis. A total of 30
images per condition were captured on 910 magni-
fication fluorescent microscope (DM6000 FS, Leica,
Germany). The microscope was setup to take separate
images of desmin (yellow light), nuceli (green light)
and a light microscope image of the same acquisition
area (of which representative light microscope images
are depicted in Fig. 1). Images were analysed using
Image J (Java) software (National Institutes of Health,
USA). Morphology was assessed by determination of
myotube diameter, number of myotubes per view,
mean number of nuclei per myotube per field of view.
Myotube diameter (lm) was determined by measuring
the diameter of three equidistant points on each
myotube (left end, middle, right end) and determining
the mean of the three values as previously described
(Stevenson et al. 2005; Trendelenburg et al. 2009;
Deane et al. 2013).
Statistical analysis
Experiments were performed in duplicate, with three
separate repeats (n = 3). Data are presented as
Mean ± SD unless stated otherwise. Gene expression
and morphology data was assessed using a mixed
three-way (2 9 6 9 2) factorial ANOVA for interac-
tions between time (72 h and 7 days), treatments (DM,
T, F, PPP, T ? F, T ? PPP T ? F ? PPP) and cell
types (CON and PD). Bonferroni post hoc analyses
were then performed to establish where differences
lay. A one way ANOVA was performed for western
blots analyses to compare the effect of treatments
between each cell type at 72 h and 7 days. AP value of
\0.05 was considered statistically significant. All
statistical analyses were performed using SPSS ver-
sion 19 (IBM, Armonk, NY, USA) and Graph Pad
Prism Software (San Diego, USA).
Results
AR (flutamide) and IGF-IR (picropodophyllin)
inhibitors on testosterone-induced hypertrophy
Firstly, here we confirm from previous studies
(Sharples et al. 2011, Deane et al. 2013) that myotube
number is significantly reduced at 72 h and 7 days in
PD versus CON cells (72 h CON 1.95 ± 0.86 vs. PD
1.0 ± 0; 7 days CON 3.27 ± 0.72 vs. PD
2.50 ± 0.62; P\ 0.05; Fig. 2c, d) as was nuclei per
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myotube (7 days CON 4.93 ± 0.92 vs. PD
4.14 ± 0.69; P\ 0.05; Fig. 2e, f). Myotube diameter
was also significantly reduced at 72 h between CON
and PD cells (CON 15.88 ± 1.55 vs PD 13.40 ± 0.47,
P\ 0.05; Fig. 2a, b) but not at 7 days (CON
15.81 ± 1.40 vs PD 15.52 ± 1.89; P\ 0.05, Fig. 2a,
b). Therefore, PD cells have reduced myotubes at both
72 h and 7 days that are less hypertrophied up to
72 h resulting in less nuclei per myotube by 7 days.
Testosterone administration alone resulted in
increases in differentiation (myotube number) and
myotube hypertrophy indices (diameter and average
nuclei per myotube) in both CON and PD cells
compared to untreated myoblasts after 72 h and
7 days culture. These observations also confirm our
previous published findings highlighting the role of
testosterone administration in improving impaired
myotube hypertrophy in the PD cell types (Deane
et al. 2013). However, T was rendered inactive in its
ability to promote differentiation in CON and PD
muscle cells following its co-incubation with AR
inhibitor flutamide, resulting in no quantifiable
myotubes being observed (Fig. 1), suggesting that
the successful binding of testosterone to the AR is
fundamental in the above morphological processes.
The IGF-IR inhibitor alone, PPP, significantly
decreased myotube number compared to DM condi-
tions in CON myoblasts after 72 h (CON DM
1.95 ± 0.86 vs. CON ? PPP 1.18 ± 0.40; P B 0.05,
Fig. 2c). Although after 7 days there was still a mean
decrease in myotube number present with PPP
administration, this was not statistically significant
(CON DM 3.27 ± 0.72 vs. CON ? PPP 2.80 ± 0.70;
P = NS, Fig. 2c). The co-incubation of PPP with
testosterone abrogated the T induced increases in
myotube number after 7 days exposure in CON cells
(CON ? T 4.73 ± 0.87 vs. CON ? T ? PPP
3.45 ± 0.60; P B 0.05, Fig. 2c). In terms of myotube
diameter; in CON cells, there was no significant effect
at 72 h and 7 days between treated and un-treated
myoblasts with PPP (P = NS, Fig. 2a). Although, PPP
impaired T induced myotube number increases, the
co-incubation of testosterone and PPP still resulted in
T induced myotube hypertrophy evident via continued
increases in myotube diameter at each time point (72 h
CON ? T 19.04 ± 2.07 vs. CON ? T ? PPP
Fig. 1 Representative light microscope (920) images for CON (Panel a) and PD (Panel b) myotube morphology after 72 h and 7 days
culture with inhibitor treatments (DM control, T testosterone, F flutamide, PPP picropodophyllin)
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Fig. 2 The effect of testosterone administration and co-
incubations of flutamide (F) and Picropodophyllin (PPP) on
myotube formation and hypertrophy. Testosterone was rendered
inactive in its ability to promote differentiation in CON and PD
muscle cells following its co-incubation with AR inhibitor flu-
tamide, resulting in no quantifiable myotubes being observed at
any time point. a In CON cells, testosterone significantly
increased myotube diameter at 72 h and 7 days exposure. The
co-incubation of testosterone with Picropodophyllin did not
abrogate testosterones increases in myotube diameter at either
time point (*P B 0.05). b A similar trend occurred in PD
myoblasts with testosterone treatment significantly increasing
myotube diameter compared to un-treated cells (*P B 0.05).
The observed increases in testosterone induced hypertrophy
continued at 7 days treatment (**P B 0.05). The addition of
PPP had no effect on altering the observed increases in
hypertrophy at either time point in PDmyoblasts. c The addition
of PPP alone significantly reduced myotube number in CON
myoblasts after 72 h (*P B 0.05). Testosterone significantly
increasedmyotube number after 7 days exposure (**P B 0.001)
in CONmyoblasts, but the addition of PPP somewhat attenuated
this increase. d Significant difference (*P\ 0.05) between PD
treatments at 72 h and 7 days for myotube number. The
myotube number at 7 days in PD myoblasts was increased with
the co-incubation of testosterone and PPP compared to untreated
and PPP treated cells (**P B 0.001). e, f Testosterone signif-
icantly increased the average number of nuclei per myotube in
both CON and PD cells after 72 h (*P\ 0.05) and 7 days
(**P\ 0.05) compared to untreated cells. The co-incubation of
picropdophyllin with testosterone did not negate the observed
increases in nuclei per myotube in either cell type after 7 days
treatment. Values presented as Mean ± SD
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18.54 ± 1.45: 7 days CON ? T 19.54 ± 1.77 vs.
CON ? T ? PPP 19.23 ± 1.82; P = NS, Fig. 2a).
Additionally, PPP alone did not significantly alter
mean nuclei per myotube in CONmyoblasts after 72 h
and 7 days compared to DM treated cells (P = NS).
Finally, the co-incubation of testosterone with PPP did
not abrogate the significant increases in mean nuclei
per myotube with testosterone administration alone at
any time point (72 h CON ? T 4.68 ± 0.92 vs.
CON ? T ? PPP 3.86 ± 0.52: 7 days CON ? T
6.80 ± 1.51 vs. CON ? T ? PPP 6.50 ± 1.22;
P = NS).
In PD cells, PPP addition resulted in no significant
differences inmyotube number compared to un-treated
cells after 7 days exposure (P = NS, Fig. 2c). A
significant difference was detected between PPP alone
and the co-incubation of PPP plus testosterone for
myotube number in PD myoblasts after 7 days culture
(PD ? PPP 2.29 ± 0.61 vs. PD ? T 2.82 ± 0.98;
PD ? T ? PPP 3.36 ± 0.50; P B 0.01, Fig. 2c). For
myotube diameter, the presence of PPP had no effect
on testosterone-induced hypertrophy in PD myoblasts
at any time point studied (72 h PD ? PPP 14.00 ±
0.10 vs. PD ? T ? PPP 18.06 ± 0.83: 7 days
PD ? PPP 15.03 ± 1.14 vs. PD ? T 18.79 ± 2.10;
PD ? T ? PPP 19.87 ± 1.35; P B 0.01, Fig. 2b). In
addition, the co-incubation of PPP with testosterone
had no effect on abrogating the increases in mean
nuclei per myotube with testosterone administered
alone (PD ? T 6.58 ± 1.54 vs. PD ? T ? PPP
5.85 ± 0.86; P = NS). Overall, in terms of myotube
morphology, it appears that testosterone-induced
hypertrophy is not mediated via the IGF-IR in both
cell types as testosterone still induced appropriate
increases in myotube hypertrophy even in the presence
of the IGF-IR inhibitor. The data do, however, suggest
that Testosterones effects are fully inhibited in the
presence of flutamide, the AR inhibitor, in both cell
types, providing initial evidence for the more predom-
inant role of successful binding of T to AR versus a
secondary effect via the IGF-IR in testosterone medi-
ated myotube hypertrophy.
The effect of testosterone administration
on androgen receptor (AR) protein abundance
A testosterone dose (100 nM) was sufficient to
increase AR protein levels in both CON and PD
myoblasts for each time point. In CON myoblasts,
testosterone significantly increased AR protein levels
(arbitrary units) alone after 72 h (CON ? T 19 ± 6
vs. CON DM 7 ± 2; P = 0.045. Figure 3a and
remained elevated (although not statistically signifi-
cant) after 7 days (CON ? T 15 ± 7 vs. CON DM
6 ± 1; P = NS. Fig. 3b). The presence of AR protein
with flutamide administration alone seemed to be
completely abolished for both 72 h and 7 day blots
(Fig. 3a, b respectively). It was interesting however,
that in the testosterone plus IGF-IR inhibitor (PPP),
AR total protein was seemingly restored back to basal
levels suggesting that testosterone administration
(similar to T alone) induces increases in AR, as
expected, that are not dependent on IGF-IR (72 h
CON T 18 ± 6 % vs. CON T ? PPP 13.5 ± 4.5 %;
7 days CON T 15 ± 7 % vs. CON T ? PPP 12 ±
3 %; P = NS).
In the PD myoblasts, testosterone significantly
increased the AR protein levels, even in the presence
of Picropodophyllin after 72 h, compared to basal
control (PD ? T 41 ± 2 %; PD T ? PPP 44 ± 11 %
vs. PD DM 11 ± 6 %; P B 0.05, Fig. 3c) and at
7 days (PD ? T 42 ± 2 %; PD T ? PPP 52 ± 5 %
vs. PD DM 6 ± 1 %; P B 0.05 Fig. 3d). Flutamide
significantly abrogated testosterone induced increases
in AR protein levels after 72 h (PD ? T 41 ± 2 %vs.
PD T ? F 3 ± 2 %; P B 0.05, Fig. 4c) and 7 days
(PD ? T 42 ± 2 % vs. PD T ? F 3 ± 2 %;
P B 0.05, Fig. 3d). Furthermore, the presence of
flutamide in combination with testosterone and PPP,
decreased AR protein levels compared to testosterone
incubated with PPP (72 h PD T ? PPP 44 ± 11 % vs.
PD T ? F ? PPP 10 ± 2 %: 7 days PD T ? PPP
52 ± 5 % vs. PD T ? F ? PPP 14 ± 7 %; P B 0.05,
Fig. 3c, d) at both time points. Together with
morphological findings these data provide evidence
that testosterone increases AR total protein and this
increase is abrogated in the presence of flutamide but
not PPP, again suggesting an important role for AR
and not the IGF-IR/associated signaling in testos-
terones impact on the morphological parameters
measured in CON and PD cells.
Finally, after 72 h there were no significant differ-
ences in basal AR total protein expression between
CON and PD myoblasts (CON DM 7 ± 2 % vs. PD
DM11 ± 6 %; P = NS, Fig. 4). However, there was a
significant increase in AR in testosterone treated PD
myoblasts verses CON treated cells (PD T 41 ± 2 %
vs. CON T 18 ± 6 %; P B 0.05) after 72 h in culture.
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It is also worth noting this larger increase in AR with
testosterone in the PD cells vs. CON cells was also
shown when in the presence of IGF-IR inhibitor (PPP)
(PD T ? PPP 44 ± 11 % vs. CON T ? PPP 13.5 ±
14.5 %; P B 0.05, Fig. 4). At 7 days, testosterone also
induced a larger increase in AR in PD vs. CON
myoblasts (PD T 42 ± 2 % vs. CON T 15 ± 7 %; PD
T ? PPP 52 ± 5 % vs. CON T ? PPP 12 ± 3 %;
P B 0.05, Fig. 4). These observations provide evi-
dence towards a heightened response in PD myoblasts
to testosterone stimulated increases in AR protein
expression which may contribute to the rescuing of
differentiation in fusion impaired myoblasts that
display basally reduced myotube growth.
Fig. 3 The effect of testosterone and co-incubation treatments
on total AR protein levels in CON (a, b) and PD (c, d) myoblasts
after 72 h and 7 days. a The addition of a testosterone stimulus
alone significantly increased AR levels in CON cells after 72 h
culture (*P = 0.045). c Testosterone treatment significantly
increased AR protein levels, even in the presence of Picrop-
odophyllin for PD myoblasts (*P\ 0.05). Flutamide
administration inhibited testosterone induced increases in AR
protein levels. d Testosterone treatment significantly increased
AR protein levels, even in the presence of Picropodophyllin
(*P\ 0.05). The presence of flutamide abrogated these
increases in AR protein levels under a testosterone stimulus.
Values presented as Mean ± SEM
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Impact of testosterone plus AR and IGF-IR
inhibitors on downstream IGF-I signaling proteins
Supplementary to assessing androgen receptor protein
levels with testosterone stimulus with/without AR or
IGF-IR inhibitors, downstream protein activity of
IGF-I signaling (Akt and ERK1/2) was investigated.
Despite the IGF-IR being seemingly un-involved in
the impact of testosterone on morphological measures,
downstream signaling of the IGF-IR has been shown
to be increased with T administration (Wu et al. 2010;
Serra et al. 2011; White et al. 2012; Basualto-Alarco´n
et al. 2013), therefore warranted further investigation.
There were no significant alterations in total ERK1/2
protein levels for either cell type or over the time
course. For ERK1/2 phosphorylation, the presence of
testosterone and flutamide co-incubation treatments
significantly reduced levels at both 72 h (CON DM
30 ± 6 vs. T 28 ± 8; T ? F 3 ± 2; T ? F ? PPP
5 ± 2; P B 0.05, Fig. 5) and 7 days (CON DM
20 ± 8 vs. 21 ± 5; T ? F 3 ± 2; T ? F ? PPP
1 ± 0; P B 0.05, Fig. 5). In both CON and PD
myoblasts, testosterone alone was ineffective in
significantly increasing ERK1/2 phosphorylation at
either time point. Between cell types, there were no
significant differences in ERK1/2 phosphorylation
basally, as reported originally in Sharples et al. (2011)
or for all other treatments in the present study at either
time point.
In CON cells, after 72 h there were significant
reductions in phosporylated Akt with the presence of
flutamide in all treatments (CON DM 93.5 ± 0.5 vs. F
24.5 ± 19.5; T ? F 19 ± 17; T ? F ? PPP
33 ± 11.5; P B 0.05, Fig. 5). The presence of testos-
terone had no effect on Akt phosphorylation at either
time points in CON cells (P = N.S.). After 7 days
administration, there were no statistically significant
alterations with any of the treatments. In comparison, a
testosterone stimulus applied to the PD myoblasts
resulted in mean increases in Akt phosphorylation
Fig. 4 Comparison between total AR levels in CON and PD
myoblasts exposed to testosterone alone and in combination
with picropodophyllin after 72 h (a) and 7 days (b). Please note,
Representative blot images are summarized from Fig. 3
(figure number and lane number where these are taken from is
depicted above the blot bands) in order to enable comparisons
with CON and PD cells visually. This is because CON and PD
cell types were analyzed on separate membranes with the same
exposure time. Densiometry was comparable between mem-
branes to allow comparisons between CON and PD cells where
it was confirmed that GAPDH (detected at the time on the same
membrane) density values were not significantly different
across membranes (P[ 0.05). Data in figures is representative
of n = 3. a Testosterone significantly increased AR levels in PD
myoblasts versus CONmyoblasts after 72 h (*P B 0.05). These
increases in AR remained in the PD cells co-incubated with
picropodophyllin compared to the same treatment in CON cells
(**P B 0.05). bAt 7 days culture, the same pattern was evident,
where by Testosterone alone (*P B 0.05) and when co-
incubated with picropodophyllin (**P B 0.05) significantly
increased AR levels compared with the same treatments in
CON myoblasts. Values presented as Mean ± SEM
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(although not statistically significant), after 72 h expo-
sure. These increases were also present with the co-
incubation of PPP, yet the presence of flutamide
significantly reduced Akt phosphorylation (PD
T ? PPP 72.5 ± 10; F 6 ± 5; T ? F 8.5 ± 5;
T ? F ? PPP 10.5 ± 5.5; P B 0.05, Fig. 6). At
7 days, the average (but not significant) increases in
Akt phosphorylation with a testosterone stimulus were
no longer present in PD myoblasts. However, the
presence of flutamide was still detrimental to Akt
phosphorylation in PD cells (PD DM 93 ± 4 vs. F
9 ± 4; T ? F 7 ± 5; T ? F ? PPP 1 ± 1; P B 0.05,
Fig. 6).
Total Akt protein significantly decreased in the
presence of flutamide and picropodophyllin after 72 h
in the CON cells. The co-incubation of testosterone
Fig. 5 The effect of exogenous testosterone and co-incubations
on total and phosphorylated Akt and ERK1/2 in CON myoblasts
after 72 h (a, c, e, g) and 7 days (b, d, f, h) respectively. a Are
representative blot images for CON cells at 72 h. b Are
representative blot images for CON cells at 7 days. After 72 h
(c), flutamide presence significantly reduced Akt phosphorylation
compared to un-treated CON myoblast (*P\ 0.05). Exogenous
testosterone had no impact on alterations in Akt phosphorylation.
At 7 days (d), there were no statistically significant alterations in
phosphorylated Akt in PDmyoblasts. e The presence of flutamide
was detrimental in ERK1/2 activation (*P\ 0.05). Exogenous
testosterone did not significantly alter ERK1/2 activation levels.
f Similar to 72 h, at 7 days flutamide administration continued to
be detrimental for ERK1/2 phosphorylation (*P\ 0.05). There
were no alterations in total ERK protein at either time points.
There were no differences between cell types (CON vs. PD) for
any time point/condition. g The presence of flutamide and
picropodophyllin significantly decreased total Akt protein after
72 h compared to untreated cells (*P\ 0.05). The addition of
testosterone with picropodophyllin lead to total Akt protein levels
being similar to un-treated myoblasts and approached a
significant increase compared to picropodophyllin alone
(P = 0.09). h At 7 days, the presence of picropodophyllin and
flutamide significantly reduced Akt protein levels (*P\ 0.05),
with testosterone having little effect in combination with the
inhibitors. Values presented as Mean ± SEM
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and PPP lead to total Akt levels increasing compared
to PPP alone (CON T ? PPP 74.5 ± 16.5 vs. PPP
39 ± 10; P = 0.09, Fig. 5), back to levels observed in
un-treated CON myoblasts at 72 h (CON DM
75 ± 21). After 7 days culture, statistically significant
reductions remained for total Akt levels in all treat-
ments with PPP and flutamide (CONDM 144 ± 10 %
vs. F 20.5 ± 5; PPP 64 ± 4; T ? F ? PPP 36 ± 1;
P B 0.05, Fig. 5). In comparison, the presence of
testosterone significantly increased total Akt protein
after 72 h culture in PD myoblasts, with this obser-
vation being abrogated in the presence of flutamide
(PD DM 47.5 ± 3.5 vs. T 76.5 ± 5.5; T ? F 22 ± 4;
P B 0.05, Fig. 6). It therefore appears that testos-
terone administration increases abundance of Akt
protein levels in both cell types, which may subse-
quently influence further downstream signaling
involved in the restored myotube morphology
Fig. 6 The effect of exogenous testosterone and co-incubations
on total and phosphorylated Akt and ERK1/2 in PD myoblasts
after 72 h (a, c, e, g) and 7 days (b, d, f, h) respectively. a Are
representative blot images for PD cells at 72 h. b Are represen-
tative blot images for PD cells at 7 days. After 72 h (c),
exogenous testosterone alone increased Akt phosphorylation
(although this was not statistically significant). The co-incubation
of testosterone significantly increased phosphorylated Akt levels
which were reduced in the presence of flutamide (*P\ 0.05). At
7 days (d), the presence of flutamide significantly reduced the
levels of phosphorylated Akt in PD myoblasts (*P\ 0.05).
e There were no statistically significant alterations in with any
treatment after 72 h, although all flutamide conditions displayed a
mean trend towards reduced ERK1/2 activation. f At 7 days the
presence of flutamide was significantly detrimental for ERK1/2
phosphorylation (*P\ 0.05). g The addition of testosterone, even
in the presence of picropodophyllin, significantly increased total
Akt levels after 72 h (*P\ 0.05). h There was no longer a
significant effect of testosterone on total Akt levels after 7 days
culture. The presence of flutamide significantly decreased total
Akt levels compared to un-treatedmyoblasts (*P\ 0.05). Values
presented as Mean ± SEM
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observed in PD cells, albeit independently of the IGF-I
receptor.
Additionally, between cell types, there were signif-
icant differences in Akt phosphorylation for basal
treatments in CON and PD myoblasts, where there
was a significant reduction after 72 h in PD myoblasts
(CON DM 93.5 ± 0.5 vs PD DM 37.5 ± 19.5;
P B 0.01). However at 7 days, Akt phosphorylation
was significantly increased in PD myoblasts compared
to basal CON cells highlighting a delayed response and
may explain the delay in fusionwithin this cell type (PD
DM 93 ± 5 vs. CON DM 23 ± 5; P B 0.001). For all
other treatments between the cell types, no significant
differences were observed at any time point.
Overall, the alterations in cellular signaling provide
evidence towards a functional AR receptor being
required for normal myotube formation and hypertro-
phy in control and PD myoblasts, as flutamide reduces
these parameters with associated reductions in phos-
phorylation of ERK and Akt. Importantly, testosterone
alone appeared to have a significantly larger impact on
Akt abundance in the PD myoblasts vs. CON cells
with little effect being observed in ERK1/2 activity
and abundance following testosterone administration
in either cell type.
Effects of testosterone administration on gene
transcripts in control and PD myoblasts
Gene transcripts were analyzed to determine the
impact of treatments on selected genes involved in
muscle differentiation and myotube hypertrophy in
both CON and PD myoblasts. Testosterone signifi-
cantly increased myogenin mRNA expression in both
CON (DM 75.86 ± 12.67 vs. T 108.36 ± 18.34;
P B 0.001, Fig. 7a) and PD (DM 27.03 ± 3.02 vs. T
34.05 ± 5.03; P B 0.05, Fig. 7b) myoblasts after 72 h
exposure. After 7 days exposure, the observed
increases in myogenin with testosterone treatment
were no longer present in either cell type (P = NS). In
basal conditions, CON cells had significantly higher
expression of myogenin after 72 h compared to PD
myoblasts (CON DM 75.86 ± 12.67 vs. PD DM
27.03 ± 3.02; P B 0.01, Fig. 7b), with this effect not
observed at 7 days (P = NS, Fig. 7b). The adminis-
tration of testosterone had no impact in either cell type
on expression of MyoD, IGF-I receptor and myostatin
(P = NS). In PD myoblasts, testosterone treatment
significantly reduced AR mRNA levels after 72 h
exposure (DM 4.07 ± 2.04 vs. T 1.28 ± 0.05; P B
0.001, Fig. 7f), which is an opposite observation to
changes in AR at the protein level described above.
Flutamide administration significantly reduced
gene transcription levels
Flutamide was inhibitory, particularly for transcripts
involved in muscle differentiation (MyoD and Myo-
genin). After 7 days exposure, myogenin expression
was significantly decreased in CON cells with the
presence of flutamide in all treatments compared to
basal conditions (CON DM 69.07 ± 13.15 vs. F
2.84 ± 0.11; T ? F 2.06 ± 0.33; T ? F ? PPP
cFig. 7 Impact of exogenous testosterone and AR (Flutamide/
F)/IGF-IR (picropodophyllin/PPP) inhibitor co-incubations on
MyoD, myogenin, AR and IGF-IR mRNA in CON and PD
myoblasts after 72 h and 7 days. a Picropodophyllin alone
significantly increased MyoD levels after 72 h (*P\ 0.05). At
7 days, the presence of flutamide reduced MyoD expression
levels in CON myoblasts (**P\ 0.01). b In PD myoblasts,
testosterone had no impact on MyoD levels at either time point.
The presence of flutamide significantly reduced expression
levels after 72 h (*P\ 0.01) and 7 days (**P\ 0.01). c Testos-
terone treatment significantly increased myogenin expression
levels in CON myoblasts after 72 h (*P\ 0.001). The presence
of flutamide significantly reduced testosterone induced
increases in myogenin (*P\ 0.001). The presence of PPP did
not significantly reduce increases in myogenin under a
testosterone stimulus after 72 h culture. d In PD myoblasts,
testosterone administration increased myogenin levels
(P\ 0.05) compared to un-treated cells. This observation was
abrogated by the presence of flutamide and Picropodophyllin
(*P\ 0.05). At 7 days, there were no increases in myogenin
expression with testosterone, however the presence of flutamide
resulted in reduced levels (**P\ 0.01). There was a significant
difference between myogenin mRNA expression after 72 h and
7 days in untreated PD cells (***P\ 0.01). e Testosterone co-
incubated with flutamide significantly increased AR mRNA
expression levels after 72 h in CON myoblasts (*P\ 0.001).
This effect was significantly reduced after 7 days
(**P\ 0.002). f In PD myoblasts, there significant reductions
in AR expression with testosterone alone and in the presence of
flutamide after 72 h (*P\ 0.001). At 7 days, the addition of
flutamide alone resulted in AR expression remaining decreased
(**P\ 0.001). g In CON myoblasts, flutamide significantly
reduced IGF-IR expression (*P\ 0.05) and Picropodophyllin
significantly increased IGF-IR at the same time point
(**P\ 0.001). There were no observed alterations at 7 days
exposure. h Flutamide significantly reduced IGF-IR expression
after 72 h in PD myoblasts compared to un-treated cells
(*P\ 0.003). The presence of flutamide, after 7 days treatment,
resulted in significant reductions in IGF-IR expression com-
pared to basal conditions (**P\ 0.01). Values presented as
Mean ± SD
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6.99 ± 1.54; P B 0.01, Fig. 7a). The detrimental
effect with flutamide administration in all treatments
on myogenin expression was observed in PD myo-
blasts after 72 h exposure (PD DM 34.05 ± 5.03 vs. F
0.30 ± 0.11; T ? F 1.44 ± 1.14; T ? F ? PPP
1.83 ± 0.91; P B 0.01, Fig. 7b) and 7 days (PD DM
56.04 ± 8.50 vs. F 1.02 ± 0.08; T ? F 1.60 ± 0.73;
T ? F ? PPP 1.39 ± 0.10; P B 0.01, Fig. 7b).
Between cell types, PD myoblasts appeared to be
more susceptible to flutamide treatment thanCONcells.
Although there was no impact of flutamide at 72 h,
significant reductions in myoD expression were
observed in CON cells at 7 days with the presence of
flutamide in all treatments (CONDM1.88 ± 0.73 vs. F
0.12 ± 0.07; T ? F 0.10 ± 0.06; T ? F ? PPP
0.78 ± 0.18; P B 0.01, Fig. 7c). A similar pattern
occurred for myoD mRNA in the PD myoblasts after
72 h (PD DM 1.48 ± 0.42 vs. F 0.13 ± 0.11; T ? F
0.24 ± 0.13; T ? F ? PPP 0.34 ± 0.10; P B 0.01,
Fig. 7d) and 7 days (PD DM 1.88 ± 0.48 vs. F
0.16 ± 0.08; T ? F 0.12 ± 0.07; T ? F ? PPP
0.21 ± 0.04; P B 0.01, Fig. 7d) following exposure to
flutamide. MyoD expression was significantly reduced
in PDmyoblasts administered with flutamide compared
to the same condition in CON myoblasts (PD ? F
0.13 ± 0.11 vs. CON ? F 1.81 ± 0.12; P B 0.05)
after 72 h culture. A similar trend for MyoD expression
was observed in both testosterone plus flutamide (PD
T ? F 0.24 ± 0.13 vs. CON T ? F 3.14 ± 0.17;
P B 0.05) and PPP (PD T ? F ? PPP 0.34 ± 0.10
vs. CON T ? F ? PPP 3.05 ± 0.64; P B 0.05) co-
incubations after 72 h culture. Furthermore, the alter-
ations in myogenin expression, supports the increased
susceptibility of PD myoblasts to flutamide administra-
tion. Myogenin expression was significantly decreased
after 72 h in PD myoblasts with flutamide compared to
CON treated myoblasts (PD ? F 0.30 ± 0.11 vs.
CON ? F 65.95 ± 19.37; P B 0.05). This pattern
was further observed at 72 h in treatments where
flutamide was present (PD T ? F 1.44 ± 1.14 vs.
CON T ? F 53.98 ± 16.97; PD T ? F ? PPP
1.83 ± 0.91 vs. CON T ? F ? PPP 56.68 ± 13.65;
P B 0.05). Overall, the presence of flutamide com-
pletely abolishes MyoD and myogenin expression after
72 h and 7 days in PD myoblasts, regulatory factors
which are fundamental in the fusion of myoblasts.
In CON cells, AR expression was significantly
increased when co-incubated with testosterone after
7 days exposure (CON DM 2.76 ± 1.69 vs. T 3.16 ±
1.93; T ? F 0.49 ± 0.32; P B 0.002, Fig. 7e). To
note, the administration of PPP significantly increased
AR mRNA expression after 72 h exposure (CON DM
2.76 ± 1.69 vs. PPP 4.35 ± 1.09; P B 0.001, Fig. 7e).
In the PD myoblasts, both the presence of testosterone
and flutamide significantly reduced AR mRNA after
72 h (PD DM 4.07 ± 2.04 vs. T 1.28 ± 0.05; F
1.44 ± 0.99; T ? F ? PPP 2.79 ± 1.37; P B 0.001,
Fig. 7f). For 7 days, the presence of flutamide in
treatments significantly reduced AR expression (PD
DM 5.42 ± 2.46 vs. F 0.59 ± 0.27; T ? F 0.87 ±
0.51; T ? F ? PPP 1.70 ± 0.21; P B 0.001, Fig. 7f).
IGF-I receptor mRNA was significantly reduced
with flutamide administration after 72 h exposure in
CON cells (CON DM 1.96 ± 0.26 vs. F 0.85 ± 0.63;
P B 0.05, Fig. 7g). The addition of PPP significantly
increased IGF-I receptor expression in CON cells at
72 h (CON DM 1.96 ± 0.26 vs. PPP 3.14 ± 0.24;
P B 0.001, Fig. 7g). The presence of flutamide sig-
nificantly reduced IGF-I receptor expression in PD
myoblasts after 7 days exposure (PD DM 1.65 ±
0.69; F 0.62 ± 0.33; T ? F 0.47 ± 0.18; T ? F ?
PPP 0.57 ± 0.14; P B 0.001, Fig. 7h). Furthermore,
testosterone co-incubated with PPP decreased IGF-I
receptor mRNA expression after 7 days (PD DM
1.65 ± 0.69 vs. T ? PPP 0.90 ± 0.14; P B 0.001,
Fig. 7h).
Finally, as myostatin has recently been shown to be
responsive to androgens (Dubois et al. 2014), the
reported observations in myotube morphology with
flutamide administration may be underpinned by the
alterations in myostatin mRNA levels. The presence of
flutamide significantly increased myostatin expression
after 7 days exposure in CON myoblasts (CON DM
2.78 ± 1.32 vs. F 8.30 ± 0.85; P B 0.001, Fig. 8a).
In PD myoblasts, treatments containing flutamide
increased myostatin expression at both time points,
although this was not statistically significant. After
72 h, flutamide co-incubated with testosterone signif-
icantly increased myostatin expression in PD myo-
blasts (PD DM 3.83 ± 1.17 vs. F 6.70 ± 4.51; T ? F
11.39 ± 2.49; P B 0.001, Fig. 8b). In this experi-
ment, testosterone and PPP had no impact on
myostatin expression in either cell type. There were
significant differences in myostatin expression
between basal CON and PD myoblasts after 7 days
culture (CON DM 2.78 ± 1.32 vs. PD DM
8.99 ± 0.47; P B 0.01, Fig. 8c). Myostatin has been
observed to be detrimental in myotube size and
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inhibiting muscle differentiation, thus potentially
explaining the lack of myotube formation in the
current study, with AR inhibition (Trendelenburg et al.
2009; Dubois et al. 2014).
Discussion
Exogenous testosterone administration restores
an ageing phenotype via the androgen receptor
and Akt
The current studies aim (1) sought to investigate the
predominate pathway for mediating testosterone
induced hypertrophy as commonly the AR and IGF-I
pathway have been investigated independently (Wu
et al. 2010; Serra et al. 2011; White et al. 2012). The
alterations in myotube morphology and protein
signaling (discussed below) provide evidence towards
a pivotal role for a functional androgen receptor being
required in myotube formation and hypertrophy in
control (CON) and fusion impaired myoblasts that
display myotube atrophy (PD) and thus the original
hypothesis for both AR and IGF-IR being pivotal in
testosterone induced hypertrophy was rejected. As we
have previously published the ability of testosterone to
improve impaired fusion and myotube atrophy in the
PD myoblasts via increases myotube diameter (Deane
et al. 2013), we sought to further elucidate the cellular
and molecular mechanisms for the positive alterations
observed in the PD myoblast phenotype. The positive
effect of a testosterone stimulus on myotube morphol-
ogy in CON and PD myoblasts was accompanied by
greater myogenin expression, similar to previous
literature (Lee 2002; Wannenes et al. 2008). At the
transcriptional level, exogenous testosterone had little
Fig. 8 The effect of testosterone administration and AR/IGF-I
inhibitor co-incubations on myostatin mRNA levels in CON and
PD myoblasts after 72 h and 7 days. a There were no
statistically significant differences in myostatin levels between
treatments in CON myoblasts after 72 h. At 7 days, there were
sizeable increases in myostatin levels with flutamide present
compared to basal conditions (*P\ 0.001). bAfter 72 h, the co-
incubation of testosterone and flutamide increased myostatin
significantly compared to un-treated PD cells (P\ 0.001). At
7 days, there were no statistically different changes between
treatments in PDmyoblasts. cThere was a significant increase in
myostatin mRNA levels after 7 days culture between basal
CON and PD myoblasts (*P B 0.01). Values presented as
Mean ± SD
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impact on other genes investigated, although it
resulted in AR mRNA being significantly down-
regulated in the PD myoblasts after 72 h culture, in
contrast to the concomitant increases observed in total
AR protein. This observation may be hypothesized to
be due to a potential increase in T-AR interactions at
the protein level, leading to reduced AR transcrip-
tional activity, however this requires further investi-
gation. Also, the ability of testosterone to significantly
increase androgen receptor levels in PD myoblasts
persisted even in the presence of the IGF-I inhibitor
(picropodophyllin). The AR increases in PD myo-
blasts were significantly greater compared to testos-
terone stimulated CON myoblasts and provide
evidence for the involvement of T in rescuing the
impaired differentiation and myotube atrophy via
increases in the abundance of the androgen receptor.
This was accompanied via increases in myogenin gene
expression, furthermore when the AR was inhibited,
reductions in MyoD occurred, suggesting that andro-
gen receptor was fundamental in both the reductions in
differentiation and hypertrophy evident when incu-
bated in the presence of flutamide alone, and in
testosterone induced hypertrophy. Recently, Serra
et al. (2011) highlighted the role of IGF-I signaling
in mediating the effects of testosterone on skeletal
muscle mass. The authors noted that a testosterone
stimulus was mediated via IGF-I/IGF-IR and down-
stream signaling. The inhibition of IGF-IR was
achieved through small interference RNA compared
to the current study which utilized a substrate com-
petitor inhibitor (Picropodophyllin). Contrary to the
findings of Serra et al. (2011) we observed testos-
terone-induced hypertrophy in both cell types even in
the presence of the IGF-I receptor inhibitor, supported
by the findings of Wu et al. (2010). However, it is
worth noting that reductions in Akt and ERK activity
were only approximately 40 % in the present studies
with PPP. The most recent evidence has alluded to the
potential role of Akt/mTOR signaling in testosterone
induce hypertrophy (White et al. 2012; Basualto-
Alarco´n et al. 2013). Within the current study,
increases in downstream IGF-IR signaling (total
Akt) were apparent in the PD myoblasts only with
testosterone administration after 72 h culture, an
observation that continued even in the presence of
the IGF-IR inhibitor (PPP). PD myoblasts also had
basally reduced phosphorylated Akt at key time points
in differentiation (72 h) versus control myoblasts and
recently we demonstrated Akt inhibition (using
LY294002) has been observed to abrogate testos-
terone-induced myotube hypertrophy (Deane et al.
2013). It is important to note that acute increases in
Akt phosphorylation may have occurred earlier under
a testosterone stimulus, as previously reported (Basu-
alto-Alarco´n et al. 2013). However, the increase in Akt
abundance in both cells types and increased abun-
dance in PD versus CON cells, allied to its sustained
elevation despite IGF-IR inhibition provides support-
ive evidence for the interaction between testosterone
and Akt perhaps somewhat independently of the IGF-I
receptor. Having said this, it is important to note that in
AR inhibitor alone conditions, flutamide reduced IGF-
IRmRNA in both cell types across time points, with an
observed reduction in activity of ERK and Akt,
suggesting that IGF-IR is transcriptionally regulated
by AR and therefore its downstream effector pathway.
However, where testosterone increased AR protein
content there was no increases observed in IGF-IR
gene expression. This suggested that sufficient AR
was important to enable normal IGF-IR gene expres-
sion and downstream signaling, yet elevated levels of
AR due to testosterone had no further effect on IGF-
IR, despite testosterone increasing Akt abundance in
the presence of IGF-IR inhibitor (discussed above).
The critical role of the androgen receptor
in skeletal myotube hypertrophy
The androgen receptor has been observed to be
important in skeletal muscle development and muscle
differentiation (Wannenes et al. 2008), as the knock-
out of muscle-specific AR results in reduced muscle
mass and strength (MacLean et al. 2008). In the
present study, flutamide (AR antagonist) administra-
tion alone completely blocked myotube formation in
both CON and PD myoblasts. As aluded to above the
presence of flutamide significantly reduced IGF-IR
mRNA and Akt and ERK1/2 activation in both cell
types which provides evidence that IGF-IR is tran-
scriptionally regulated by AR and that basally (with-
out testosterone) AR is important in normal Akt and
ERK activity important in cellular differentiation and
myotube hypertrophy (Baar and Esser 1999; Jones
et al. 2001; Rommel et al. 2001; Adi et al. 2002).
Importantly, the presence of flutamide abrogated
testosterone induced hypertrophy in both cell types,
suggesting AR being a critical pathway for the
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improvements in myotube hypertrophy under a testos-
terone stimulus. Furthermore, in both CON and PD
myoblasts with the presence of flutamide, there was a
significant increase in myostatin mRNA expression.
Myostatin (GDF-8; TGF-b family member) has been
observed to be a negative regulator of muscle mass and
more specifically inhibit muscle differentiation and
myotube size (McCroskery et al. 2003; Amthor et al.
2004; Trendelenburg et al. 2009). Recently Braga
et al. (2012), reported the effects of testosterone on
TGF-b signaling where testosterone stimulated mus-
cle cell proliferation and differentiation due to inhi-
bition of this pathway and via follistatin up-regulation.
Furthermore, Dubois et al. (2014) have highlighted
promotion of myostatin gene expression as a direct
target for androgen receptor mediated transcription
through studies investigating satellite-cell specific AR
knockout mice (satARKO). The authors found that
satARKO mice had reduced muscle strength, yet
because of AR’s transcription factor role in myostatin
expression, the authors actually saw a sixfold reduc-
tions in myostatin. This perhaps shows that AR maybe
even be more powerful in controlling muscle mass
than myostatin because there was still a drop in
strength in satARKO mice but the corresponding drop
in myostatin could not compensate in order to
increase strength. Indeed, this was confirmed where
muscle hypertrophy in response to androgens was
enhanced in myostatin knockout mice. This conflicts
with the findings of the current study, where the
inhibition of the AR lead to increased myostatin
levels, leading to reduced myotube differentiation,
however this phenotype has been previously observed
in human muscle cells with the addition of myostatin
(Trendelenburg et al. 2009). In the current study,
exogenous testosterone had no positive effect on
myostatin expression in either cell type, although
previous animal and in vitro studies have observed
testosterone-induced reductions in myostatin levels
(Kawada et al. 2006; Mendler et al. 2007; Kovacheva
et al. 2010; Deane et al. 2013), findings that warrant
future investigation in this model. There is also
evidence that myostatin inhibits satellite cell activa-
tion, proliferation, and differentiation (Wagner et al.
2005; Kawada et al. 2006; Sinha-Hikim et al. 2006),
through perturbation of Akt and mTOR signalling
(Trendelenburg et al. 2009). In the current study, Akt
abundance was increased with a testosterone stimulus
in PD cells and reduced in the presence of flutamide.
Therefore, the reduced Akt in the flutamide conditions
may have been as a consequence of the increased
myostatin levels observed. Thus administration of
testosterone shows strong potential to enhance hyper-
trophy in fusion impaired myoblasts that display
myotube atrophy directly via the AR, however also
highlights the importance of total Akt abundance.
Indeed, previous literature has implicated testosterone
enhancing Akt/mTOR pathway signalling (Wu et al.
2010; White et al. 2012; Basualto-Alarco´n et al. 2013)
and previously we have provided evidence towards its
role in aged myoblasts (Deane et al. 2013). Therefore
the regulation of muscle hypertrophy under a testos-
terone stimulus appears to be controlled by AR, IGF-
IR, Akt and myostatin interactions. Future work needs
to address the mechanisms of increased alterations in
Akt abundance following testosterone administration
despite blocking upstream IGF-IR.
Conclusion
In conclusion, testosterones ability to improve differ-
entiation and myotube hypertrophy occurred predom-
inately via increases in AR and Akt abundance in both
CON and PD cells, with fusion impaired cells (PD)
showing an increased responsiveness to T induced AR
levels. Finally, T induced increases in myotube
hypertrophy (but not early differentiation) occurred
independently of upstream IGF-IR input, however it
was apparent that normal AR function in basal
conditions (without testosterone) was required for ad-
equate IGF-IR gene expression and down-
stream ERK/Akt activity.
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